Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2021-12-23
DOI
10.1093/jac/dkab494
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase 3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP)
- (2021) Matthew G. Johnson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections – SMART United States 2018–2019
- (2021) James A. Karlowsky et al. BMC MICROBIOLOGY
- Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
- (2021) Laura Puzniak et al. Infectious Diseases and Therapy
- Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017
- (2020) Jean-Louis Vincent et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia
- (2020) Luzelena Caro et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial
- (2020) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of the in vitro susceptibility of ceftolozane-tazobactam to the cumulative susceptibility rates of standard antibiotic combinations when tested against Pseudomonas aeruginosa from ICU patients with bloodstream infections or pneumonia
- (2019) Dee Shortridge et al. Open Forum Infectious Diseases
- Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world
- (2019) Jason M. Pogue et al. EXPERT OPINION ON PHARMACOTHERAPY
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016)
- (2019) James A. Karlowsky et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Antimicrobial Activity of Ceftolozane-Tazobactam Tested against Contemporary (2015-2017) P. aeruginosa Isolates from a Global Surveillance Program
- (2019) Dee Shortridge et al. Journal of Global Antimicrobial Resistance
- Culture-Negative Septic Shock Compared With Culture-Positive Septic Shock
- (2018) Shravan Kethireddy et al. CRITICAL CARE MEDICINE
- Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program
- (2018) Dee Shortridge et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–17)
- (2018) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Comparing current US and European guidelines for nosocomial pneumonia
- (2018) Daire N. Kelly et al. CURRENT OPINION IN PULMONARY MEDICINE
- Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers
- (2018) Cecilia G. Carvalhaes et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
- (2018) George H Talbot et al. JOURNAL OF INFECTIOUS DISEASES
- The efficacy and safety of tazobactam/ceftolozane in combination with metronidazole in Japanese patients with complicated intra-abdominal infections
- (2018) Hiroshige Mikamo et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs
- (2017) B. Borgatta et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
- (2017) Antoni Torres et al. EUROPEAN RESPIRATORY JOURNAL
- How Should We Treat Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae?
- (2017) Jean-François Timsit et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module
- (2016) Víctor Daniel Rosenthal et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
- (2016) Andre C. Kalil et al. CLINICAL INFECTIOUS DISEASES
- Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014
- (2016) Lindsey M. Weiner et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
- (2015) Joseph Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia
- (2015) Alan J. Xiao et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
- (2015) Florian M Wagenlehner et al. LANCET
- Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management
- (2015) Keith S. Kaye et al. PHARMACOTHERAPY
- The impact of multidrug resistance on outcomes in ventilator-associated pneumonia
- (2014) Rudy Tedja et al. AMERICAN JOURNAL OF INFECTION CONTROL
- International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module
- (2014) Víctor Daniel Rosenthal et al. AMERICAN JOURNAL OF INFECTION CONTROL
- Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009–2012
- (2014) Helio S. Sader et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies
- (2013) Wilhelmina G Melsen et al. LANCET INFECTIOUS DISEASES
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Microbial Etiologies of Hospital‐Acquired Bacterial Pneumonia and Ventilator‐Associated Bacterial Pneumonia
- (2010) Ronald N. Jones CLINICAL INFECTIOUS DISEASES
- Antimicrobial Therapy for Life-threatening Infections: Speed is Life
- (2010) Duane J. Funk et al. CRITICAL CARE CLINICS
- Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock
- (2009) Anand Kumar et al. CHEST
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started